Serial levels of CA 19-9 and CEA in colonic cancer.

Novis, Ben; Glück, E; Thomas, Peter; Steele, Glenn; Zurawski, Vincent R.; Stewart, Robyn A.; Lavin, Philip T.; Zamcheck, Norman

doi:10.1200/jco.1986.4.6.987

Cited by 30 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CA19-9 assay detects a mucin containing a pentasaccharide epitope (fucopentaose II) considered to be a tumor marker in pancreatic adenocarcinoma [25]. Abnormal CA19-9 serum levels were also found in patients with cholangiocarcinoma [26], colorectal cancer [27], gastric cancer [28], and a wide range of benign conditions, such as liver diseases, ascending cholangitis, and pancreatitis [29]. The preoperative CA19-9 level has been reported to be a prognostic factor for pancreatic cancer [30] and cholangiocarcinoma [31].…”

Section: Discussionmentioning

confidence: 99%

Elevated Preoperative Serum CA19‐9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

Chen

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

Serum levels of the tumor marker CA19-9 have been reported to be elevated in patients with hepatocellular carcinoma (HCC), but its clinicopathologic significance is still unknown. A cohort of 304 patients undergoing surgical resection for HCC and having preoperative CA19-9 data was enrolled in this study. Serum CA19-9 levels were correlated with clinicopathologic factors. Univariate and multivariate analyses were performed to determine the predictors of patient survival. On receiver operating characteristic curve analysis, the cut off value of CA19-9 was determined to be 27 U/mL. One hundred and six patients had preoperative CA19-9 values >27 U/mL. High serum CA19-9 levels did not correlate with patient age, sex, viral status, α-fetoprotein level, tumor size, tumor grade, tumor stage, multiplicity, and vascular invasion. Patients with elevated preoperative CA19-9 levels had lower 10-year survival than those without CA19-9 elevation. Multivariate analysis revealed that CA19-9 level, tumor grade, and tumor size are independent prognostic factors for long-term survival. In conclusion, a preoperative CA19-9 value >27 U/mL is associated with poor prognosis after resection for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Elevated Preoperative Serum CA19‐9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

Chen

et al. 2013

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…Elevated serum CA 19-9 levels can be found in various gastrointestinal cancers, including gastric cancer, pancreatic cancer, colorectal cancer etcetera. [20][21][22] As for ascitic fluid CA 19-9, Mezger et al reported that determination of CA 19-9 in ascites, at a cut-off level of 30 U/mL, was specific (1 00%) but not sensitive (52%) enough in the diagnosis of malignancy-related ascites.2 Our series showed a better result, 65.5% sensitivity and 93.6% specificity, with a cut-off level of 50 U/mL. The assessment of CA 19-9 assay in the current study, though highly specific, is still not sensitive enough.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of tumour markers and serum‐ascites albumin gradient in the diagnosis of malignancy‐related ascites

Chen¹,

Wang²,

Lu³

et al. 1994

J of Gastro and Hepatol

View full text Add to dashboard Cite

To determine the clinical value of tumour markers in the diagnosis of malignancy-related ascites (not including hepatocellular carcinoma), serum and ascitic fluid levels of carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 19-9, tissue polypeptide antigen and serum-ascites albumin gradient were determined in 66 patients with cirrhotic ascites, 28 patients with hepatocellular carcinoma and ascites, and 29 patients with malignancy-related ascites. Three tumour markers and serum-ascites albumin gradient showed significant difference between patients with malignancy-related ascites and those without: serum carcinoembryonic antigen (26.4 +/- 31.5 vs 4.8 +/- 4.6 ng/mL, P < 0.01), ascitic fluid carcinoembryonic antigen (118.4 +/- 196.5 vs 2.0 +/- 1.4 ng/mL, P < 0.01), ascitic fluid carbohydrate antigen 19-9 (12,933 +/- 25,496 vs 23 +/- 67 U/mL, P < 0.01) and serum-ascites albumin gradient (1.1 +/- 0.4 vs 2.0 +/- 0.4 g/dL, P < 0.01). At the best cut-off levels chosen from near 95% of the data in those without malignancy-related ascites, the sensitivity, specificity and accuracy to diagnose malignancy-related ascites were, respectively, 65.5%, 93.6%, 87.0% using serum carcinoembryonic antigen > or = 10 ng/mL; 69.0%, 94.7%, 88.6% using ascitic fluid carcinoembryonic antigen > or = 5 ng/mL; 65.5%, 93.6%, 87.0% using ascitic fluid carbohydrate antigen 19-9 > or = 50 U/mL; 62.1%, 98.9%, 90.2% using serum-ascites albumin gradient < 1.1 g/dL. Although serum-ascites albumin gradient offered the best diagnostic accuracy and specificity, its sensitivity was not good enough. Our study indicates that serum-ascites albumin gradient and tumour markers are not sensitive parameters in the diagnosis of malignancy-related ascites.

show abstract

“…In our group’s NV1020 trial, all patients experienced partial response and CEA reduction following viral and chemotherapy, and the patient with the greatest radiographic tumor reduction in response to one dose of virus alone (39%) also had the greatest reduction of CEA level (75%) (17;21). While CEA levels vary greatly between patients, relative change in CEA in a single patient has been correlated with tumor recurrence and tumor burden (80–83). Accordingly, CEA could serve as a marker for oHSV efficacy during treatment, perhaps guiding future dosing strategies in individual patients.…”

Section: Clinical Trialsmentioning

confidence: 99%

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Carpenter

Carson

Fong

2010

Seminars in Oncology

View full text Add to dashboard Cite

The mortality of colorectal carcinoma often results from the progression of metastatic disease, which is predominantly hepatic. Though recent advances in surgical, locoregional, and systemic therapies have yielded modest survival improvements, treatment of these aggressive lesions is limited to palliation for the vast majority of patients. Oncolytic viral therapy represents a promising novel therapeutic modality that has achieved tumor regression in several preclinical and clinical models. Evidence further suggests that locoregional viral administration may improve viral efficacy while minimizing toxicity. This study will review the theories behind hepatic arterial infusion of oncolytic virus, as well as herpes viral design, preclinical data, and clinical progress in regional liver therapy using oncolytic virus to treat hepatic colorectal carcinoma metastases.

show abstract

Serial levels of CA 19-9 and CEA in colonic cancer.

Cited by 30 publications

References 10 publications

Elevated Preoperative Serum CA19‐9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

Elevated Preoperative Serum CA19‐9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection

Clinical value of tumour markers and serum‐ascites albumin gradient in the diagnosis of malignancy‐related ascites

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Contact Info

Product

Resources

About